LIVZON PHARMA (01513) · Company profile · Eqvero

LIVZON PHARMA

01513HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	11.9 bn CNY	11.7 bn CNY	12.33 bn CNY	12.52 bn CNY	11.93 bn CNY
Cost of revenue	3.56 bn CNY	3.58 bn CNY	3.93 bn CNY	3.92 bn CNY	3.86 bn CNY
Research and development expense	937.95 m CNY	1.03 bn CNY	1.33 bn CNY	1.43 bn CNY	1.15 bn CNY
Selling, general and administrative expense	4.18 bn CNY	3.87 bn CNY	4.25 bn CNY	4.55 bn CNY	4.55 bn CNY
Operating profit after depreciation	2.63 bn CNY	2.54 bn CNY	1.92 bn CNY	1.93 bn CNY	1.92 bn CNY
Operating profit before depreciation	3.2 bn CNY	3.11 bn CNY	2.76 bn CNY	2.58 bn CNY	2.36 bn CNY
EBIT	2.63 bn CNY	2.54 bn CNY	1.92 bn CNY	1.93 bn CNY	1.92 bn CNY
EBITDA	3.2 bn CNY	3.11 bn CNY	2.76 bn CNY	2.58 bn CNY	2.36 bn CNY
Interest expense	57.21 m CNY	88.61 m CNY	102.09 m CNY	97.55 m CNY	84 m CNY
Profit before tax	2.86 bn CNY	2.81 bn CNY	2.38 bn CNY	2.33 bn CNY	2.25 bn CNY
Income tax expense	451.01 m CNY	501.66 m CNY	485.07 m CNY	375.01 m CNY	293.59 m CNY
Income before extraordinary items	2.02 bn CNY	2.06 bn CNY	1.95 bn CNY	1.91 bn CNY	1.78 bn CNY
Common dividends	1.27 bn CNY	984.14 m CNY	1.25 bn CNY	1.54 bn CNY	1.21 bn CNY
Total dividends	1.27 bn CNY	984.14 m CNY	1.25 bn CNY	1.54 bn CNY	1.21 bn CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.